A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
DRUG

AZD9977

Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.

DRUG

Itraconazole

Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY